Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy

Anders Kirkegaard Jensen, Katerina Chatzidionysiou, Christopher Kirkegaard Torp, Anne Sofie Sørensen, Helene Broch Tenstad, Valentin S. Schäfer, Marie Kostine, Søren Jacobsen, Jan Leipe*, Tue Wenzel Kragstrup


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

32 Downloads (Pure)


Introduction: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is a relatively new disease entity caused by ICI agents during cancer therapy. Reactive arthritis (ReA) is a well-known disease entity caused by urogenital or gastrointestinal bacterial infection or pneumonia. In this sense, ICI-IA and ReA are both defined by a reaction to a well-specified causal event. As a result, comparing these diseases may help to determine therapeutic strategies. Methods: We compared ICI-IA and ReA with special focus on pharmacological management. Specifically regarding treatment, we conducted a literature search of studies published in the PubMed database. Inclusion criteria were studies on treatment with non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GC), or disease modifying antirheumatic drugs (DMARDs) in ICI-IA or ReA. During systematic selection, 21 studies evaluating ICI-IA and 14 studies evaluating ReA were included. Results: In ICI-IA, prospective and retrospective studies have shown effects of non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoid (GC), sulfasalazine (SSZ), methotrexate (MTX), hydroxychloroquine (HCQ) and TNFi. In ReA, retrospective studies evaluated NSAIDs and GC. A randomized controlled trial reported the effect of SSZ, and a retrospective study reported the effect of MTX and SSZ in combination with tumor necrosis factor alpha inhibition (TNFi). For both entities, small case reports show treatment effects of interleukin 6 receptor inhibition (IL-6Ri). Discussion: This literature review identified both similarities and differences regarding the pathogenesis and clinical features of ReA and ICI-IA. Studies on treatment reported effectiveness of NSAIDs, GC, MTX, SSZ and TNFi in both diseases. Further, small case reports showed effects of IL-6Ri.

TidsskriftBiomedicine and Pharmacotherapy
Antal sider9
StatusUdgivet - apr. 2022

Bibliografisk note

Funding Information:
TWK was supported by a grant from Independent Research Fund Denmark ( 9039–00015B ).

Funding Information:
T. Kragstrup has received the Gilead Nordic Fellowship grant, has engaged in educational activities receiving speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, UCB, and Abbvie, has received consultancy fees from Bristol-Myers Squibb, Gilead, Galapagos, and UCB, and is co-founder and clinical developer in iBiotech ApS developing diagnostic and therapeutic solutions for people with autoimmune diseases and cancer. J. Leipe received grant/research support from: Novartis, Pfizer; Abbvie, BMS, Gilead, Janssen, Sanofi; honoraria for consulting or speaking: Abbvie, BMS, Galapagos, Janssen-Cilag, Gilead, Lilly, Medac, MSD, Novartis, Pfizer, Roche/Chugai, Sanofi, UCB. V.Schäfer received grant/research support from: Novartis, Hexal, Lilly, Roche, Celgene, University of Bonn, honoraria for consulting or speaking: Chugai, AbbVie, Celgene, Sanofi, Lilly, Pfizer, Amgen, BMS, Roche, Gilead, Novartis, BMS, Medac, Sanofi, Lilly, Pfizer, Janssen, Roche, Schire, Onkowissen.


Dyk ned i forskningsemnerne om 'Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy'. Sammen danner de et unikt fingeraftryk.